Functional Pulmonary Capillary Surface Area in BPA for CTEPH

Assessment of Recovery of Functional Capillary Surface Area in Patients Undergoing a Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension [CTEPH] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty [BPA] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area [FCSA] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.

Study Overview

• Status: Recruiting
• Conditions: Hypertension, Pulmonary; Pulmonary Thromboembolisms
• Intervention / Treatment: Other: Measurement of pulmonary functional capillary surface area

Detailed Description

Chronic thromboembolic pulmonary hypertension [CTEPH] affects approximately 3% of patients with a prior pulmonary embolism. In CTEPH patients, the acute pulmonary emboli do not resolve but instead become organized in the pulmonary artery walls causing physical luminal obstruction and impeding forward blood flow. Pulmonary vascular resistance rises, and right heart failure can ultimately develop. Currently, there are 3 therapeutic options for treating CTEPH: 1) pulmonary thromboendarterectomy involving surgical removal of the clots; 2) balloon pulmonary angioplasty involving opening of the narrow areas using angioplasty balloons; 3) medical therapy for distal disease using the soluble guanylate cyclase stimulator riociguat.

Balloon pulmonary angioplasty (BPA), depending on the number of narrow pulmonary artery segments that are opened, can provide immediate hemodynamic benefit in appropriate patients. Although the hemodynamics usually do not completely normalize after a single BPA session, cardiac output may increase and mean pulmonary artery pressure may fall. It is unclear how much pulmonary microvasculature must be restored to obtain this benefit, both in terms of number of segments, and in terms of the amount of downstream pulmonary microvasculature that must be regained.

The investigators have developed a technique in humans that assesses functional capillary surface area (FCSA). It involves measuring the metabolism of injected trace quantities of 3H-benzoyl Phe-Ala-Pro (BPAP), as the peptide passes through the lung circulation, and interacts with the capillary endothelial surface area. The investigators have established the range of normal in humans, studied the effects of exercise, and explored the reduction in FCSA in disease, including various types of pulmonary hypertension. Most germane to the present study, our previous work (Orfanos et al J Throm Hemostas 2008) demonstrated that the downstream capillary bed in CTEPH is functionally normal but FCSA is reduced because of upstream arteriolar blockage by organized thrombi. The average FCSA in untreated CTEPH is decreased by approximately 50%. Some of this FCSA should be immediately available to accept blood flow (recruitment) once the corresponding upstream segmental pulmonary artery is reopened by BPA.

Hypotheses:

1. The measured FCSA will immediately increase in CTEPH patients after BPA.
2. The amount of FCSA regained (recruited) will be proportional to the number of pulmonary arterial segments dilated.
3. The decrease in mean pulmonary arterial pressure towards normal may be a better indicator of FCSA regained than will be reduction in pulmonary vascular resistance.

Techniques:

All our routine techniques for BPA remain unchanged. The patients have a systemic arterial line and a pulmonary artery thermodilution catheter inserted for hemodynamic measurements prior to BPA, and the measurements are repeated after BPA. The only added procedure is that there will be 2 injections of 3H-BPAP via the "proximal" port of the thermodilution catheter, at the time of hemodynamic measurements pre-BPA (PRE) and post-BPA (POST). Systemic arterial blood will be collected at each timepoint for analysis of BPAP metabolism.

Recruitment and Consent:

The protocol has already been approved by the JGH IRB. Patients with newly diagnosed CTEPH who are deemed to be candidates for BPA will be approached in our Pulmonary Hypertension/CTEPH clinic. The research procedures and purpose will be explained and they will be given a consent form to review, and their questions will be answered. Should they agree to participate, the consent form will be signed and they will be included in the study.

Sample size:

Because BPAP metabolism will be measured pre and post BPA in the same patient, they will act as their own controls. The investigators are planning a study of a continuous response variable from matched pairs of study subjects. Prior data indicate that the baseline standard deviation of FCSA in the CTEPH population is 784. If the true FCSA difference in the mean response of matched pairs is 505 (33% increase in FCSA), the investigators will need to study 27 subjects to be able to reject the null hypothesis that this response difference is zero with probability (power) 0.9. If the mean response is 765 (50% increase), the investigators will need to study 13 subjects. The Type I error probability associated with this test of this null hypothesis is 0.05. The investigators will assess the magnitude of response after 10 subjects are completed and, based on that, reduce the n where possible. But the investigators have planned to study at least 40 subjects if needed.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Lyda Lesenko, MD; Phone Number: 22833 514-340-8222; Email: llesenko@jgh.mcgill.ca
• Study Contact Backup: Name: David Langleben, MD; Phone Number: 5143407531; Email: david.langleben@mcgill.ca

Study Locations

• Canada
  • Quebec
    • Montreal, Quebec, Canada, H3W 2C4
      • Recruiting
      • David Langleben
      • Contact: David Langleben; Phone Number: 5143407531; Email: david.langleben@mcgill.ca
      • Principal Investigator: David Langleben, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

Exclusion Criteria:

• Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,
• Presence of patent foramen ovale

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pre and post BPA	Other: Measurement of pulmonary functional capillary surface area; Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in pulmonary functional capillary surface area	Measurement of transpulmonary metabolism of benzoyl-Phe-Ala-Pro	4 hours

Collaborators and Investigators

• Sponsor: Jewish General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): March 23, 2023
• Primary Completion (Estimated): January 30, 2028
• Study Completion (Estimated): January 30, 2028

Study Registration Dates

• First Submitted: January 30, 2023
• First Submitted That Met QC Criteria: January 30, 2023
• First Posted (Actual): February 9, 2023

Study Record Updates

• Last Update Posted (Estimated): September 23, 2025
• Last Update Submitted That Met QC Criteria: September 22, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Respiratory Tract Diseases; Lung Diseases; Embolism and Thrombosis; Embolism; Hypertension; Pulmonary Embolism; Hypertension, Pulmonary
• Other Study ID Numbers: 00-034 (3)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No